Actuate Therapeutics Inc ACTU
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 23.93M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 12
Valuation
|
Metric
|
ACTU
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 9.02 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
ACTU
Financial Strength
|
Metric
|
ACTU
|
|---|---|
Quick Ratio | 1.72 |
Current Ratio | 1.80 |
Interest Coverage | −1,078.36 |
Quick Ratio
ACTU
Profitability
|
Metric
|
ACTU
|
|---|---|
Return on Assets (Normalized) | −146.40% |
Return on Equity (Normalized) | −511.92% |
Return on Invested Capital (Normalized) | −521.96% |
Return on Assets
ACTU
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|l&D^Ql | LOCK|Vn^t^ | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|#d%&%? | LOCK|SbfX | $71B | |||
| argenx SE ADR
ARGX
| LOCK|r>sJh^ | LOCK|z!X | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|CtBb&C | LOCK|gV | $36B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|z%m%CZ | LOCK|$F>& | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|Kj<Cn@n | LOCK|gV^K | $26B | |||
| Moderna Inc
MRNA
| LOCK|nBq#^hM | LOCK|@Rt | $25B | |||
| Incyte Corp
INCY
| LOCK|lCZ$%? | LOCK|w?& | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|!##kZn | LOCK|r<q | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|$%v@<> | LOCK|Fdh | $16B |
United States